Skip to main content

You are here:

Usage of Omics Technology for Identification of Critical Mediators and Pathways in Patients with Hidradenitis Suppurativa (HS)

Hidradenitis suppurativa is an inflammatory skin disease affecting approximately 1% of the population and Adalimumab (Humira) is a medication that has been licenced for the treatment of patients with HS. We are trying to further understand how Humira works in HS. We hope to determine the factors in the body which may cause improvements for the disease with Humirea treatments

ELIGIBILITY CRITERIA

If you are over 18 years old and have a diagnosis of H.S. You will be seen by a dermatologist and if clinically suitable for Humira then a member of the research team will work with you on the remaining inclusion criteria.

Therapeutic Area
Dermatology
Type of Study
Clinical Trial
Study Status
Open Recruiting
Sponsor
U.C.D. and via a strategic partnership with Science Foundation Ireland and Abbvie
Principal Investigator
Professor Brian Kirby
Contact
Sean.kearns@ucd.ie